Novozymes (BMV:NSIS N) - Aandelenkoers, Nieuws & Analyse

NSIS N Overzicht aandelen

Produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally.

Over het bedrijf

NSIS N fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	3/6
Prestaties in het verleden	3/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

De winst zal naar verwachting met 19.52% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een hoog schuldenniveau

Novonesis A/S Concurrenten

Grupo México. de

BMV:GMEXICO B

Mex$858.5b

CEMEX. de

BMV:CEMEX CPO

Mex$173.2b

Industrias Peñoles. de

BMV:PE&OLES *

Mex$116.7b

Asian Paints

NSEI:ASIANPAINT

₹2.9t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Novozymes
Historische aandelenkoersen
Huidige aandelenkoers	DKK 911.11
52 Week Hoogtepunt	DKK 938.65
52 Week Laag	DKK 730.70
Bèta	0.48
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	0.47%
33 jaar verandering	-31.10%
5 jaar verandering	0.96%
Verandering sinds IPO	15.79%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NSIS N	MX Chemicals	MX Markt
7D	0%	-2.2%	1.3%
1Y	0.5%	-21.3%	8.9%

Rendement versus industrie: NSIS N overtrof de MX Chemicals industrie, die het afgelopen jaar een rendement -20.9 % opleverde.

Rendement versus markt: NSIS N presteerde slechter dan MX Market, dat het afgelopen jaar een rendement van 4.5 % opleverde.

Prijsvolatiliteit

Is NSIS N's price volatile compared to industry and market?
NSIS N volatility
NSIS N Average Weekly Movement	n/a
Chemicals Industry Average Movement	4.3%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	6.4%
10% least volatile stocks in MX Market	2.9%

Stabiele aandelenkoers: NSIS N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van NSIS N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1925	6,577	Ester Baiget	www.novonesis.com

Novonesis A/S Samenvatting

Hoe verhouden de winst en inkomsten van Novozymes zich tot de beurswaarde?
NSIS N fundamentele statistieken
Marktkapitalisatie	Mex$419.73b
Inkomsten(TTM)	Mex$7.22b
Inkomsten(TTM)	Mex$42.74b

58.1x

Koers/Winstverhouding

9.8x

P/S-verhouding

Is NSIS N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NSIS N resultatenrekening (TTM)
Inkomsten	DKK 17.90b
Kosten van inkomsten	DKK 8.18b
Brutowinst	DKK 9.72b
Overige uitgaven	DKK 6.70b
Inkomsten	DKK 3.02b

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

May 03, 2024

Winst per aandeel (EPS)	6.51
Brutomarge	54.32%
Nettowinstmarge	16.89%
Schuld/Eigen Vermogen Verhouding	51.6%

Hoe presteerde NSIS N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.7%

Huidig dividendrendement

88%

Uitbetalingsratio

NSIS N Overzicht aandelen

Beloningen

Risicoanalyse

Novonesis A/S Concurrenten

BMV:GMEXICO B

Mex$858.5b

BMV:CEMEX CPO

Mex$173.2b

BMV:PE&OLES *

Mex$116.7b

NSEI:ASIANPAINT

₹2.9t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021